RESUMEN
BACKGROUND: Drug-eluting stents (DESs) have improved clinical outcomes of patients undergoing percutaneous coronary intervention (PCI). Nevertheless, adverse events related to previously treated lesion still occur. We sought to evaluate the incidence and predictors of target lesion failure (TLF) in patients undergoing contemporary DES implantation. METHODS: Patient-level data from 6 prospective, randomized trials were pooled, and DES treatment outcomes were analyzed at up to 5â¯years. Primary outcome was TLF (cardiac death, target lesion revascularization, or target vessel myocardial infarction). Cox proportional-hazards model was used to identify predictors of TLF. RESULTS: Overall, 10,072 patients were included in the analysis. TLF rate was 1.7%, 4.3%, and 11.9% at 30â¯days, 1â¯year, and 5â¯years, respectively. The only independent predictor of TLF at 30â¯days was stent length (hazard ratio [HR] 1.017, 95% CI 1.011-1.024, Pâ¯<â¯.0001). Moderate/severe calcification, stent length and post procedural diameter sthenosis were predictors between 30â¯days to 1â¯year but not at 1 to 5â¯years. Reference vessel diameter was the only lesion-related predictor at 5â¯years (Pâ¯=â¯.003). Clinical predictors of TLF between 30â¯days and 1â¯year were diabetes and hypertension (Pâ¯<â¯.01 for both), and between 1 and 5â¯years, diabetes (HR 1.40, 95% CI 1.13-1.73, Pâ¯=â¯.002), prior coronary artery bypass grafting (HR 2.52, 95% CI 1.92-3.30, Pâ¯<â¯.0001), and prior PCI (HR 1.29, 95% CI 1.02-1.64, Pâ¯=â¯.04) predicted TLF. CONCLUSIONS: Predictors of TLF vary in the early, late, and very late postprocedural periods. Reference vessel diameter was the only lesion-related predictor of long-term TLF; clinical predictors were diabetes, prior coronary artery bypass grafting, and prior PCI.
Asunto(s)
Reestenosis Coronaria/terapia , Stents Liberadores de Fármacos/estadística & datos numéricos , Infarto del Miocardio/etiología , Intervención Coronaria Percutánea/estadística & datos numéricos , Falla de Prótesis , Antineoplásicos/uso terapéutico , Everolimus/uso terapéutico , Femenino , Cardiopatías/mortalidad , Humanos , Masculino , Persona de Mediana Edad , Paclitaxel/uso terapéutico , Intervención Coronaria Percutánea/métodos , Modelos de Riesgos Proporcionales , Estudios Prospectivos , Ensayos Clínicos Controlados Aleatorios como Asunto/estadística & datos numéricos , Factores de Tiempo , Insuficiencia del TratamientoRESUMEN
OBJECTIVES: We aimed to evaluate the safety and efficacy of the dedicated Tryton side branch (SB) stent for the treatment of true bifurcations involving large SBs. BACKGROUND: Bifurcation lesions are associated with lower procedural success and a higher risk of adverse cardiac events. Provisional stenting (PS) is currently the default approach for the treatment of bifurcation lesions. The Tryton stent is a dedicated bifurcation stent system for the treatment of true bifurcation lesions. METHODS: We performed an individual-patient-data pooled post-hoc analysis of the Tryton Pivotal randomized controlled trial and post-approval Confirmatory Study. Only patients with true bifurcations involving a SB ≥ 2.25 mm in diameter were included. The primary endpoint was non-inferiority of Tryton compared with PS for target vessel failure (TVF) at 1 year. RESULTS: Of the 411 patients meeting the criteria for enrolment, 287 patients were treated with the Tryton stent and 124 with PS. Procedural success was higher in the Tryton group (95.4 versus 82.3%, P < 0.0001). TVF at 1 year was 8.1% in the Tryton group and 9.7% in the PS group, meeting the pre-specified criteria for non-inferiority established for the randomized controlled trail (pnon-inferiority = 0.02). At 9-month angiographic follow-up, SB diameter stenosis was significantly lower in the Tryton group (29.3 ± 21.9 versus 41.1 ± 17.5, P = 0.0008) and in-segment binary restenosis (diameter stenosis ≥ 50%) was higher in the PS group (19.0 versus 34.2%, respectively, P = 0.052). CONCLUSIONS: In patients with true bifurcations involving a large SB, treatment with the Tryton SD Stent was clinically non-inferior to PS and showed favorable angiographic outcomes.